Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders

A polyacrylic acid, cellulose ether technology, applied in sexual diseases, medical preparations containing active ingredients, drug combinations, etc., can solve problems such as tablet retention, inability to achieve solid-gel transition, etc. Improves chemical and physical stability, prolongs the effect of dosing intervals

Inactive Publication Date: 2009-07-08
POLICHEM SA
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In these cases, low shear forces from body motions fail to achieve the solid-gel transition, resulting in prolonged tablet retention in the vaginal cavity without performing any drug release

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
  • Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
  • Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0084] Embodiment 1 (comparative example)

[0085] Ciclopirox olamine 100 mg controlled-release bioadhesive vaginal tablets with lot number P06-037 were produced according to conditions known in the art.

[0086] Qualitative-quantitative formulations are shown in Table I.

[0087] Table I

[0088] components Dosage (mg / tablet) 1. Ciclopirox olamine

[0089] The method consisted of blending ingredients 1-8 followed by direct compression using a rotary tablet press (Officine Ronchi). A tablet weighing 760 mg with a hardness of 201N is obtained. Components No. 2 and No. 3 are components in the hydrophilic matrix (i).

Embodiment 2

[0091] Ciclopirox olamine 100 mg controlled release bioadhesive vaginal tablets with lot number P06-038 were produced according to the teachings of the present invention.

[0092] Tablets were prepared as described in Example 1.

[0093] Qualitative-quantitative formulations are shown in Table II.

[0094] Table II

[0095] components Quantity (mg / tablet) 1. Ciclopirox olamine

2. Hydroxypropyl methylcellulose 4,000cps

3. Polycarbophil

4. Sodium Carboxymethyl Cellulose XL

5. Microcrystalline cellulose

6. Anhydrous Dicalcium Phosphate

7. Mannitol

8. Silica

9. Magnesium stearate 100.0

139.05

46.35

76.00

111.24

46.35

231.75

4.63

4.63 total 760.00

[0096] Components No. 2, No. 3 and No. 4 are components in the hydrophilic matrix (i).

[0097] A tablet weighing 760 mg with a hardness of 248N is obtained.

Embodiment 3

[0099] Structural analysis measurements were carried out on the tablets described in Example 1 (Lot No. P-06-037) and Example 2 (Lot No. P-06-038) in order to evaluate their bioadhesive properties and their degree of swelling. Tests for significant differences between means were performed by one-way ANOVA. Differences at the P<0.05 level were considered significant.

[0100] The bioadhesive properties were evaluated by a structure analyzer [1] and porcine vaginal mucosa was used as biosubstrate in order to simulate vaginal application.

[0101] A software-controlled dynamometer (AG / MC Acquati) with a 5 daN force cell was used to measure the separation force.

[0102] Sample Preparation

[0103] vaginal mucosa

[0104] The connective tissue was stripped from the vaginal mucosa obtained from the slaughterhouse using surgical scissors and stored at -20°C until use. The mucous membrane was thawed and carefully inspected visually for any defects prior to experimental applicat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A hydrophilic matrix is disclosed which comprises: a) at least one polyacrylic acid derivative in preferred amounts of 0.5 - 40%, b) at least one cellulose ether in preferred amounts of 30 - 90% and c) at least one disintegrant in preferred amounts of 2 - 50%, with respect to the weight of the matrix. This matrix is used in combination with at least one pharmaceutically acceptable active principle for manufacturing solid bioadhesive controlled release formulations for the treatment of vaginal disorders, such as vulvovaginal candidiasis, bacterial vaginosis or trichomoniasis. The matrix is used in solid formulations in amounts of about 5 - 60%, preferably 20-40%, and the active principle in amounts of about 2- 70 %, preferably 5-50% with respect to the weight of the formulation.

Description

field of invention [0001] The invention relates to a bioadhesive controlled-release tablet for vaginal drug delivery for treating female genital diseases. Background of the invention [0002] Vaginal delivery is an important route of drug delivery for local and systemic diseases. However, despite the many advantages of this route of administration, such as self-insertion and avoidance of the first-pass effect, there is a wide inter-individual variability and has not been widely exploited. [0003] Furthermore, commercial forms such as creams, foams, gels, douches, and tablets are believed to reside in the vaginal cavity for a relatively short period of time through the self-cleaning action of the vagina and often require multiple daily doses to ensure desired required therapeutic effect. [0004] To prolong the residence time in the vaginal cavity, bioadhesive therapeutic systems have been developed in the form of semi-solid and solid dosage forms. [0005] Bioadhesive s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K31/496A61P15/02
CPCA61K9/0039A61K31/496A61K9/2054A61P15/00A61P15/02A61P31/00A61P31/02A61P31/04A61P31/10A61P31/12A61P33/00A61P33/02A61K47/34A61K47/38A61K9/20
Inventor S·德路易吉布鲁斯基F·马兰德
Owner POLICHEM SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com